USFDA issues 6 observations to Biocon’s Malaysian facility

6 observations on Form 483 issued to Biocon

117
USFDA
Picture: Pixabay

Last Updated on September 28, 2021 by The Health Master

Biotechnology major Biocon on Saturday said the US health regulator has issued six observations after the inspection of the manufacturing facility of its Malaysian subsidiary Biocon Sdn Bhd.

Pharma Biocon
Representational image

The US Food and Drug Administration (USFDA) conducted an on-site pre-approval inspection of the company’s Malaysian subsidiary Biocon Sdn Bhd’s manufacturing facility for Insulin Aspart between September 13 and September 24, Biocon said in a statement.

“At the conclusion of the inspection, the agency has issued a Form 483 with a total of 6 observations across Drug Substance, Drug Product and Devices Facilities,” it added.

A Biocon spokesperson said the company is confident of addressing these observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA), which will be submitted to the USFDA in the stipulated time.

“We do not expect the outcome of this inspection to impact our commercialisation plans for insulin Aspart in the US. Biocon Biologics remains committed to global standards of quality and compliance,” the spokesperson added.

As per the US health regulator, an FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Act.

Amaris Clinicals completes USFDA Audit with NIL observations: Chennai

Lupin gets these 7 observations from USFDA for Goa Plant

USFDA inspection ends with ‘Zero’ observations: Alkem

Alkem gets two observations from USFDA for USA plant

Dr Reddy’s gets 3 observations from USFDA for US-based API plant

Alembic Pharma gets 5 observations from

PM to launch Pradhan Mantri Digital Health Mission on 27th

Govt approves Medical Device Park off Yamuna Expressway

24 weeks cap for MTP in special cases comes into force

We need to be vigilant towards counterfeit products: ASPA

Govt recommends imposition of Anti Dumping duty on APIs

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner